primary advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer

DBCOND0173198Female Urogenital and Breast DiseasesGenital Neoplasms, Female

primary advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer is the indication for 1 drug in DrugBank. It is covered by 2 curated, structured indications.

Classified under
Indicated drugs

What you can answer from here — as of October 23, 2026

1Indicated drugWith each drug's targets and mechanism
Listed above
2Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in

Which approved drugs for primary advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In